D75-4590 | CAS# 384376-42-5 | Beta-1,6-glucan inhibitor antifungal

MedKoo Cat#: 571472 | Name: D75-4590

Description:

WARNING: This product is for research use only, not for human or veterinary use.

D75-4590 is a β-1,6-Glucan inhibitor. These inhibitors work as antifungal drugs by targeting the fungal cell wall. As glucan is a major component of the cell wall, specifically β-1,6-Glucan, these drugs can help fight fungal infections by degrading glucan or stopping production by inhibiting its synthase. D75-4590 is a pyridobenzimidazole derivative that achieves this function, and is effective against Candida strains (even fluconazole-resistant strains). D11-2040 and D21-6076 are antifungal derivatives of D75-4590.

Chemical Structure

D75-4590

CAS#384376-42-5

Theoretical Analysis

MedKoo Cat#: 571472

Name: D75-4590

CAS#: 384376-42-5

Chemical Formula: C21H27N5

Exact Mass: 349.2266

Molecular Weight: 349.48

Elemental Analysis: C, 72.17; H, 7.79; N, 20.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

D75-4590; D754590; D75 4590

IUPAC/Chemical Name

1-{[2-(Diethylamino)ethyl]amino}-2-ethyl-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile

InChi Key

DMKNXKIUSPUYQP-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H27N5/c1-5-16-15(4)17(14-22)21-24-18-10-8-9-11-19(18)26(21)20(16)23-12-13-25(6-2)7-3/h8-11,23H,5-7,12-13H2,1-4H3

SMILES Code

N#CC1=C(C)C(CC)=C(NCCN(CC)CC)N2C3=CC=CC=C3N=C21

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

There is increasing morbidity and mortality resulting from invasive fungal infections (IFIs) and antifungal drug resistance. As a result, several drug therapies are addressing the need by discovering and designing new antifungal drug targets and mechanisms, specifically against the most common fungi causing IFIs: Candida, Cryptococcus, and Aspergillus species. Existing drugs (polyenes, azoles, and echinocandins) have limited clinical efficacy, narrow antifungal spectrum, unfavorable pharmacokinetic profiles, significant side effects, drug−drug interactions, and resistance issues.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 349.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kitamura A, Someya K, Hata M, Nakajima R, Takemura M. Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis. Antimicrob Agents Chemother. 2009 Feb;53(2):670-7. doi: 10.1128/AAC.00844-08. Epub 2008 Nov 17. PubMed PMID: 19015325; PubMed Central PMCID: PMC2630612. 2: Kitamura A, Someya K, Okumura R, Hata M, Takeshita H, Nakajima R. In vitro antifungal activities of D11-2040, a beta-1,6-glucan inhibitor, with or without currently available antifungal drugs. Biol Pharm Bull. 2010;33(2):192-7. PubMed PMID: 20118539. 3: Liu N, Tu J, Dong G, Wang Y, Sheng C. Emerging New Targets for the Treatment of Resistant Fungal Infections. J Med Chem. 2018 Jan 16. doi: 10.1021/acs.jmedchem.7b01413. [Epub ahead of print] PubMed PMID: 29294275.